SCHEMBL581338

SCHEMBL581338

[CH]1Cc2ccsc2CN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1025859 0.70
SCHEMBL11977449 0.65
SCHEMBL11088 0.64
SCHEMBL31021243 0.62 PNMT (0.42)
Hydrochloric Acid SCHEMBL1427992 0.62 PNMT (0.69)
SCHEMBL6511764 0.61 PNMT (0.61)
SCHEMBL7795528 0.61 PNMT (0.45)
SCHEMBL17948230 0.59
Hydrochloric Acid SCHEMBL366688 0.59 PNMT (0.95)
SCHEMBL7300096 0.59

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 392 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118319913-A Compositions and methods for treating polycythemia 迪斯克医药公司 2024-07-12 CN disclosed
CN-118319914-A Compositions and methods for treating anemia associated with ribosomal disorders 迪斯克医药公司 2024-07-12 CN disclosed
EP-4387613-A1 CONJUGATES OF MONOCYCLIC BETA-LACTAMS AND SIDEROPHORE MIMETICS University of Notre Dame du Lac (US) 2024-06-26 EP disclosed
EP-4373832-A1 PROCESSES OF MAKING ONAPRISTONE AND INTERMEDIATES THEREOF Context Biopharma Inc. (US) 2024-05-29 EP disclosed
US-20240165077-A1 COMPOSITIONS AND METHODS FOR TREATING NEUROLOGIC DISEASES COGNITION THERAPEUTICS, INC. (US) 2024-05-23 US disclosed
US-11981636-B2 Compositions for treating neurodegenerative diseases COGNITION THERAPEUTICS, INC. (US) 2024-05-14 US disclosed
US-20240150288-A1 ISOINDOLINE COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE COGNITION THERAPEUTICS, INC. (US) 2024-05-09 US disclosed
CN-117979967-A Methods of treating erythropoiesis protoporphyria, X-linked protoporphyria, or congenital erythropoiesis porphyria with glycine transporter inhibitors 迪斯克医药公司 2024-05-03 CN disclosed
US-20240139188-A1 Arylamide Compounds For Treatment And Prevention Of Fungal Infections INNOVATION PHARMACEUTICALS INC (US) 2024-05-02 US disclosed
US-11964961-B2 Heteroaromatic compounds and their use as dopamine D1 ligands PFIZER INC. (US) 2024-04-23 US disclosed
EP-1080095-A1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) NOVO NORDISK A/S (DK) 2001-03-07 EP disclosed
EP-1080068-A1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES Novo Nordisk A/S (DK) 2001-03-07 EP disclosed
EP-1062218-A1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) NOVO NORDISK A/S (DK) 2000-12-27 EP disclosed
EP-1062204-A1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) NOVO NORDISK A/S (DK) 2000-12-27 EP disclosed
EP-1062199-A1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) NOVO NORDISK A/S (DK) 2000-12-27 EP disclosed
WO-1999046244-A1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) NOVO NORDISK A/S (DK) 1999-09-16 WO disclosed
WO-1999046267-A1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) NOVO NORDISK A/S (DK) 1999-09-16 WO disclosed
WO-1999046236-A1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) NOVO NORDISK A/S (DK) 1999-09-16 WO disclosed
WO-1999046237-A1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES NOVO NORDISK A/S (DK) 1999-09-16 WO disclosed
WO-1999046268-A1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) NOVO NORDISK A/S (DK) 1999-09-16 WO disclosed